Ultragenyx Received its Third Buy in a Row

After Canaccord Genuity and Wedbush assigned a Buy rating to Ultragenyx in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Eric Schmidt maintained a Buy rating on Ultragenyx (NASDAQ: RARE) yesterday. The company’s shares closed yesterday at $57.96.

According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.4% and a 60.6% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.

Ultragenyx has an analyst consensus of Strong Buy, with a price target consensus of $72.33.

See today’s analyst top recommended stocks >>

Based on Ultragenyx’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $81.73 million. In comparison, last year the company had a GAAP net loss of $68.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a clinical-stage biotechnology company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. It intends to build therapies to address these clinically underserved diseases.